CSPC PHARMACEUT.GR. ADR4 - Asset Resilience Ratio
CSPC PHARMACEUT.GR. ADR4 (CVGU) has an Asset Resilience Ratio of 5.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CVGU current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how CSPC PHARMACEUT.GR. ADR4's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CSPC PHARMACEUT.GR. ADR4 assets under control.
Liquid Assets Composition Over Time
This chart breaks down CSPC PHARMACEUT.GR. ADR4's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does CSPC PHARMACEUT.GR. ADR4 carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.78 Billion | 5.94% |
| Total Liquid Assets | €2.78 Billion | 5.94% |
Asset Resilience Insights
- Limited Liquidity: CSPC PHARMACEUT.GR. ADR4 maintains only 5.94% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CSPC PHARMACEUT.GR. ADR4 Industry Peers by Asset Resilience Ratio
Compare CSPC PHARMACEUT.GR. ADR4's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Annual Asset Resilience Ratio for CSPC PHARMACEUT.GR. ADR4 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for CSPC PHARMACEUT.GR. ADR4.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.94% | €2.78 Billion ≈ $3.25 Billion |
€46.70 Billion ≈ $54.59 Billion |
+2.63pp |
| 2024-12-31 | 3.32% | €1.47 Billion ≈ $1.72 Billion |
€44.39 Billion ≈ $51.90 Billion |
+0.99pp |
| 2023-12-31 | 2.33% | €1.08 Billion ≈ $1.26 Billion |
€46.28 Billion ≈ $54.11 Billion |
-6.23pp |
| 2022-12-31 | 8.56% | €3.57 Billion ≈ $4.18 Billion |
€41.77 Billion ≈ $48.83 Billion |
+4.40pp |
| 2021-12-31 | 4.15% | €1.44 Billion ≈ $1.69 Billion |
€34.74 Billion ≈ $40.62 Billion |
-- |
About CSPC PHARMACEUT.GR. ADR4
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more